About us
Tridek-One is a spin-off from INSERM that develops first-in-class therapeutic agonistic antibodies targeting immune checkpoint inhibitory receptors for the treatment of autoimmune and inflammatory diseases.
The company primarily focuses on the research and development of first-in-class anti-CD31 agonistic modalities designed to restore the immune balance. Anti-CD31 agonistic antibodies have the potential to provide targeted immunomodulatory activity with a favorable safety profile in diseases with high unmet clinical needs.
Fully leveraging its understanding of inhibitory checkpoint receptor modulation and agonistic antibodies engineering, a second discovery program was initiated for a novel therapeutic target.
Tridek-One is financed by leading European investors and led by an experienced management team.
About us
Tridek-One Therapeutics, a spin-off from INSERM, is pioneering a platform-based approach that leverages CD31 ITIM receptor agonism to modulate ITAM receptor activation, offering a novel strategy for the treatment of a wide range of autoimmune and inflammatory diseases.
The company primarily focuses on developing a pipeline of first-in-class bispecific antibodies with IgG-like PK features targeting CD31 and cell-specific ITAM receptors, enabling the selective targeting of pathogenic immune cells.
Our company is financed by leading European investors and led by an experienced management team.
Our Team
Management
Scientific team
Antibody-mediated CD31 agonism inhibits
activatory signal induced by ITAM receptors
Scientific rationale
Mode of action of ITIM receptors
- CD31 belongs to a family of receptors harboring immunoreceptor tyrosine-based inhibitory motifs (ITIMs).
- ITIMs recruit and activate the tyrosine phosphatases SHP-1 and SHP-2, which can inhibit signaling pathways downstream of various ITAM immunoreceptors, leading to suppression of leukocyte activation.
Targeting CD31 and therapeutic opportunities
CD31 also known as PECAM-1 is a unique ITIM immunoreceptor due to its expression on the surface of cells from the innate and the adaptive immune system. CD31 agonists could potentially modulate:
- Neutrophil activation and recruitment during inflammation helping to promote the resolution of inflammation and prevent tissue damage;
- T cell activation by inhibiting signaling pathways downstream of TCRs leading to decreased T cell activation, proliferation, and cytokine production;
- B cell signaling by inhibiting the activation of the BCR leading to decreased B cell activation, proliferation, and antibody production.
Possible indications allow for niche to blockbuster drugs potential
Antibody-mediated CD31 agonism inhibits
activatory signal induced by ITAM receptors
Scientific rationale
Mode of action of ITIM receptors
- CD31 (PECAM-1) belongs to a family of receptors harboring immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and has a broad immune cell expression.
- ITIMs recruit and activate the tyrosine phosphatases SHP-1 and SHP-2, which can inhibit signaling pathways downstream of various ITAM immunoreceptors, leading to suppression of cell activation.
- Fc-silent devoid of effector functions (ADCC, CDC, ADCP)
Targeting CD31 and therapeutic opportunities
CD31 also known as PECAM-1 is a unique ITIM immunoreceptor due to its expression on the surface of cells from the innate and the adaptive immune system. CD31 agonists could potentially modulate:
- Neutrophil activation and recruitment during inflammation helping to promote the resolution of inflammation and prevent tissue damage;
- T cell activation by inhibiting signaling pathways downstream of TCRs leading to decreased T cell activation, proliferation, and cytokine production;
- B cell signaling by inhibiting the activation of the BCR leading to decreased B cell activation, proliferation, and antibody production.
Possible indications allow for niche to blockbuster drugs potential
Science
Mode of action of ITIM receptors
- CD31 (PECAM-1) belongs to a family of receptors harboring immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and has a broad immune cell expression.
- ITIMs recruit and activate the tyrosine phosphatases SHP-1 and SHP-2, which can inhibit signaling pathways downstream of various ITAM immunoreceptors, leading to suppression of cell activation.
Technology Platform
- Dual-targeting bispecific antibodies combining anti-CD31 and ITAM-targeting
- Enables cell-specific ITIM-mediated immunomodulation to restore immune balance with reduced risk of immunosuppression
Antibody-mediated CD31 agonism inhibits activatory signal induced by ITAM receptors
Antibody-mediated CD31 agonism inhibits
activatory signal induced by ITAM receptors
Board Of Directors
Members
Observers
Scientific founders
Investors
Tridek-One announced on September 15 2022 that it has closed a €16 million ($16.1M) new financing round led by Swiss Pureos Bioventures with the participation of new investors Bpifrance and Bioqube Ventures (Belgium), as well as historical investors AdBio partners and Advent Life Sciences. The funds are primarily be used to identify development candidates against auto-immune diseases, to conduct IND-enabling studies and to further build the organization.
The company previously raised €3M ($3.02M) in a first round in 2019 involving AdBio partners (FR) and Advent Life Sciences (UK).
Tridek-One Therapeutics announced on September 15th, 2022, that it has closed a new financing round led by Swiss Pureos Bioventures with the participation of new investors Bpifrance and Bioqube Ventures (Belgium), as well as historical investors AdBio partners (FR) and Advent Life Sciences (UK).
Tridek-One Therapeutics has raised a total of €11 million to-date in equity and secured €1.9 million in Deeptech financing from Bpifrance.
News
TRIDEK-ONE SECURES €1.9 MILLION IN DEEP TECH FINANCING FROM BPIFRANCE
Financial support will enable company to pursue the identification and development of first-in-class anti-CD31 agonistic modalities designed to restore the immune balance.
TRIDEK-ONE CLOSES A €16 MILLION FINANCING ROUND TO DEVELOP FIRST-IN-CLASS IMMUNE CHECKPOINT AGONISTS
Paris, France, September 15, 2022 – Tridek-One SAS, a biotech start-up and leader in the research and development of CD31 agonists to restore the immune balance, closed a € 16 million new round of financing led by Pureos Bioventures with participation of new investors bpifrance and Bioqube Ventures and historical investors
TRIDEK-ONE raises € 3 million from Advent France Biotechnology and Advent Life Sciences
Tridek One, Paris, June 4, 2019 – Tridek-One, a biotech company specialized in the development of products for the treatment of immune disorders, is pleased to announce a first round of funding of € 3 million with leading investors Advent France Biotechnology and Advent Life Sciences.